---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-024728"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2021-12-09T23:59:59+00:00"
generated_at: "2026-06-28T02:26:55.547517+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aurinia reports positive long-term safety data from AURORA 2 study of LUPKYNIS in lupus nephritis

## Summary
- 116 voclosporin-treated patients showed stable mean eGFR over 36 months; +2.7 mL/min increase from baseline vs control.
- Serious adverse event rates lower in voclosporin group (19% vs 24% control); no deaths vs 4 in control.
- Mean UPCR lower in voclosporin group at all time points over three years.
- Withdrawal rate lower in voclosporin group (12.9% vs 15.0% control); drug well tolerated overall.

## SEC filing metadata
- accession: 0001628280-21-024728
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2021-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828021024728/0001628280-21-024728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828021024728/auph-20211209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-024728
- JSON: https://secwatch.observer/filing/0001628280-21-024728.json
- Plain text: https://secwatch.observer/filing/0001628280-21-024728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.